3 unchanged sentences
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
−Removed: MARCH 31, 2023 AND DECEMBER 31, 2022
+Added: JUNE 30, 2023 AND DECEMBER 31, 2022
(in thousands)
−Removed: MARCH 31, 2023
+Added: JUNE 30, 2023
DECEMBER 31, 2022
15 unchanged sentences
Other long term liabilities
−Removed: Long-term lease liability
+Added: Operating lease liability
Deferred income taxes
3 unchanged sentences
authorized - 50,000 shares;
−Removed: issued and outstanding - March 31, 2023, 3,628 shares and December 31, 2022, 3,628 shares
+Added: issued and outstanding - June 30, 2023, 3,629 shares and December 31, 2022, 3,628 shares
Accumulated other comprehensive loss
7 unchanged sentences
CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
−Removed: THREE MONTHS ENDED MARCH 31, 2023 AND MARCH 31, 2022
+Added: THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND JUNE 30, 2022
(in thousands, except per share amounts - unaudited)
Three Months Ended
+Added: Six Months Ended
+Added: June 30, 2023
+Added: June 30, 2022
+Added: June 30, 2023
+Added: June 30, 2022
Cost of goods sold
17 unchanged sentences
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
−Removed: FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND MARCH 31, 2022
+Added: FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND JUNE 30, 2022
(in thousands - unaudited)
−Removed: THREE MONTHS ENDED
+Added: Six Months Ended
CASH FLOWS FROM OPERATING ACTIVITIES:
1 unchanged sentence
cash provided by operating activities
−Removed: Provision for losses on accounts receivable
+Added: Provision for (recovery of) losses on accounts receivable
Amortization of Right-of-Use Assets
12 unchanged sentences
Property and equipment
+Added: Intangible assets
Net cash used in investing activities
1 unchanged sentence
Proceeds from issuance of common stock - options
+Added: Common stock purchased and retired
Payment of dividends
−Removed: Net cash provided by/(used in) financing activities
+Added: Net cash used in financing activities
Effect of exchange rate changes on cash
7 unchanged sentences
UTAH MEDICAL PRODUCTS, INC.
−Removed: AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY FOR THE
−Removed: THREE MONTHS ENDED MARCH 31, 2023 AND MARCH 31, 2022
+Added: THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(In thousands - unaudited)
1 unchanged sentence
Stockholders'
+Added: Income (Loss)
Balance at December 31, 2022
−Removed: Shares issued upon exercise of employee stock options for cash
+Added: Shares issued upon exercise of employee
+Added: stock options for cash
Stock option compensation expense
2 unchanged sentences
Balance at March 31, 2023
+Added: Shares issued upon exercise of employee
+Added: stock options for cash
+Added: Stock option compensation expense
+Added: Foreign currency translation adjustment
+Added: Common stock dividends
+Added: Balance at June 30, 2023
Balance at December 31, 2021
−Removed: Shares issued upon exercise of employee stock options for cash
+Added: Shares issued upon exercise of employee
+Added: stock options for cash
Stock option compensation expense
2 unchanged sentences
Balance at March 31, 2022
+Added: Shares issued upon exercise of employee
+Added: stock options for cash
+Added: Stock option compensation expense
+Added: Common stock purchased and retired
+Added: Foreign currency translation adjustment
+Added: Common stock dividends
+Added: Balance at June 30, 2022
see notes to consolidated condensed financial statements
8 unchanged sentences
(2) Recent Accounting Standards.
−Removed: The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.
−Removed: (3) Inventories at March 31, 2023 and December 31, 2022 consisted of the following:
−Removed: March 31, 2023
+Added: The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.
+Added: (3) Inventories at June 30, 2023 and December 31, 2022 consisted of the following:
+Added: June 30, 2023
December 31, 2022
3 unchanged sentences
(4) Stock-Based Compensation.
−Removed: At March 31, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.
+Added: At June 30, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.
The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation .
This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors.
−Removed: In the quarters ended March 31, 2023 and 2022, the Company recognized $ 50 and $ 43 , respectively, in stock based compensation cost.
+Added: In the quarters ended June 30, 2023 and 2022, the Company recognized $ 50 and $ 40 , respectively, in stock based compensation cost.
+Added: In the six months ended June 30, 2023 and 2022, the Company recognized $ 100 and $ 83 , respectively, in stock based compensation cost.
(5) Warranty Reserve.
4 unchanged sentences
The amount of this reserve is adjusted, as required, to reflect its actual experience.
−Removed: Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2022 or March 31, 2023.
−Removed: (6) 1Q 2023 global revenues (USD) by product category:
+Added: Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2022 or June 30, 2023.
+Added: (6) Global 2Q 2023 revenues (USD) by product category:
Gynecology/Electrosurgery/Urology
Blood Pressure Monitoring and Accessories
+Added: Global 1H 2023 revenues (USD) by product category:
+Added: Gynecology/Electrosurgery/Urology
+Added: Blood Pressure Monitoring and Accessories
(7) Distribution Agreement Purchase.
2 unchanged sentences
(CSI) on February 1, 2019.
−Removed: The $ 21,000 purchase price represents an identifiable intangible asset which is being straight-line amortized and recognized as part of G&A expenses over the 7 month remaining life, as of the end of 1Q 2023, of the prior CSI agreement with Femcare.
+Added: The $ 21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&A expenses over a remaining 4 -month life as of June 30, 2023 of the prior CSI distribution agreement with Femcare.
(8) Earnings Per Share.
Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period.
−Removed: Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2023.
+Added: Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2023.
The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:
1 unchanged sentence
Three months ended
+Added: Six months ended
Weighted average shares, basic
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.